Gables Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $877K | Buy |
36,400
+914
| +3% | +$23.9K | 0.32% | 69 |
|
|
2026
Q1 | $996K | Sell |
35,486
-1,125
| -3% | -$30K | 0.42% | 53 |
|
|
2025
Q4 | $912K | Buy |
36,611
+500
| +1% | +$12.6K | 0.39% | 54 |
|
|
2025
Q3 | $920K | Sell |
36,111
-5,141
| -12% | -$127K | 0.39% | 57 |
|
|
2025
Q2 | $1,000K | Sell |
41,252
-7,900
| -16% | -$184K | 0.47% | 50 |
|
|
2025
Q1 | $1.25M | Buy |
49,152
+800
| +2% | +$20.9K | 0.62% | 40 |
|
|
2024
Q4 | $1.28M | Buy |
48,352
+150
| +0.3% | +$4.07K | 0.62% | 39 |
|
|
2024
Q3 | $1.39M | Buy |
48,202
+4,049
| +9% | +$118K | 0.7% | 37 |
|
|
2024
Q2 | $1.24M | Buy |
44,153
+3,925
| +10% | +$108K | 0.65% | 38 |
|
|
2024
Q1 | $1.12M | Sell |
40,228
-1,225
| -3% | -$34K | 0.62% | 40 |
|
|
2023
Q4 | $1.19M | Sell |
41,453
-1,550
| -4% | -$46.9K | 0.74% | 36 |
|
|
2023
Q3 | $1.43M | Sell |
43,003
-3,100
| -7% | -$110K | 0.99% | 27 |
|
|
2023
Q2 | $1.69M | Sell |
46,103
-50
| -0.1% | -$1.95K | 1.11% | 26 |
|
|
2023
Q1 | $1.88M | Hold |
46,153
| – | – | 1.32% | 20 |
|
|
2022
Q4 | $2.36M | Sell |
46,153
-550
| -1% | -$26.4K | 1.72% | 14 |
|
|
2022
Q3 | $2.04M | Buy |
46,703
+50
| +0.1% | +$2.43K | 1.64% | 18 |
|
|
2022
Q2 | $2.45M | Sell |
46,653
-450
| -1% | -$22.9K | 1.85% | 14 |
|
|
2022
Q1 | $2.44M | Sell |
47,103
-4,100
| -8% | -$213K | 1.53% | 17 |
|
|
2021
Q4 | $3.02M | Buy |
51,203
+1,075
| +2% | +$53.3K | 1.8% | 14 |
|
|
2021
Q3 | $2.16M | Sell |
50,128
-200
| -0.4% | -$8.86K | 1.41% | 18 |
|
|
2021
Q2 | $1.97M | Sell |
50,328
-20,862
| -29% | -$811K | 1.35% | 21 |
|
|
2021
Q1 | $2.58M | Sell |
71,190
-500
| -0.7% | -$17.8K | 1.41% | 23 |
|
|
2020
Q4 | $2.64M | Sell |
71,690
-2,554
| -3% | -$93.7K | 1.54% | 20 |
|
|
2020
Q3 | $2.58M | Buy |
74,244
+2,609
| +4% | +$91.5K | 1.67% | 19 |
|
|
2020
Q2 | $2.22M | Buy |
71,635
+666
| +0.9% | +$22.6K | 1.54% | 20 |
|
|
2020
Q1 | $2.2M | Buy |
70,969
+2,232
| +3% | +$76.1K | 1.81% | 16 |
|
|
2019
Q4 | $2.56M | Buy |
68,737
+1,054
| +2% | +$37.5K | 1.72% | 14 |
|
|
2019
Q3 | $2.31M | Buy |
67,683
+1,581
| +2% | +$57.5K | 1.63% | 17 |
|
|
2019
Q2 | $2.72M | Buy |
66,102
+106
| +0.2% | +$4.21K | 2.22% | 12 |
|
|
2019
Q1 | $2.66M | Sell |
65,996
-1,344
| -2% | -$53.8K | 2.14% | 12 |
|
|
2018
Q4 | $2.79M | Sell |
67,340
-1,370
| -2% | -$56.9K | 2.43% | 9 |
|
|
2018
Q3 | $2.87M | Sell |
68,710
-843
| -1% | -$32.5K | 2.19% | 9 |
|
|
2018
Q2 | $2.38M | Buy |
69,553
+1,588
| +2% | +$54.3K | 1.94% | 14 |
|
|
2018
Q1 | $2.29M | Buy |
+67,965
| New | +$2.34M | 2.02% | 14 |
|
Other funds holding PFE
Gables Capital Management's PFE Position: Q2 2026 in Review
Gables Capital Management increased its Pfizer (PFE) stake by 2.6% in Q2 2026, buying an estimated $23.9K and bringing the position to 36,400 shares worth $877K. The position accounts for 0.32% of the portfolio, ranked #69.
Gables Capital Management first reported a position in PFE in Q1 2018 and has held it in 34 quarters since. The position peaked at $3.02M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Gables Capital Management held 36,400 shares of Pfizer worth $877K as of Q2 2026.
- Gables Capital Management bought 914 Pfizer shares in Q2 2026, an estimated $23.9K.
- Pfizer made up 0.32% of Gables Capital Management's portfolio in Q2 2026, its #69 holding.
- Gables Capital Management first reported a position in Pfizer in Q1 2018 and has held it in 34 quarters since.
- Gables Capital Management's Pfizer position peaked at $3.02M in Q4 2021.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Gables Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.